HCPLive
OCTOBER 27, 2024
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
Dr. Smith's ECG Blog
OCTOBER 27, 2024
This was submitted by a paramedic, Hailey Kennedy A late 50s male called 911 following 2 hours of chest pain that started while working at his desk. He reported the crushing chest pain radiated down his left arm. Pt took an antacid with no relief and decided to call at the request of his wife. Here is his EMS ECG: What do you think? This was sent to me with no clinical information, and my initial impression viewing it on my phone was "It’s a tricky one.
HCPLive
OCTOBER 27, 2024
In this interview, Neal Bhatia, MD, and Laura Korb Ferris, MD, PhD, spoke on their Fall Clinical Conference talk titled ‘Beyond the Biopsy: Other Methods To Help Us Manage Skin Cancer.
Med Page Today
OCTOBER 27, 2024
(MedPage Today) -- As a physician who is hard of hearing, I was excited to learn about FDA's authorization of Apple's newest AirPods, which will come with the capability to convert into hearing aids. If the AirPods live up to their promise, individuals.
Heart Sisters
OCTOBER 27, 2024
What can patients do when we suspect that a doctor’s words or behaviours when delivering a diagnosis seem uncertain?
HCPLive
OCTOBER 27, 2024
Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.
Open Heart
OCTOBER 27, 2024
Background Echocardiography, cardiac magnetic resonance and cardiac 18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging play key roles in the diagnosis and management of cardiac sarcoidosis (CS), but the relative value of each modality in predicting outcomes has yet to be determined. This study sought to determine the prognostic importance of multimodality imaging data over and above demographic characteristics and left ventricular ejection fraction (LVEF).
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Open Heart
OCTOBER 27, 2024
Aims We set out to explore associations between a ‘mitral-specific’ cardiac damage score (m-CDS) and survival outcomes in mitral regurgitation (MR) and compare the performance of the m-CDS and an ‘aortic-specific’ CDS (a-CDS) in patients with MR within the large National Echo Database of Australia. Methods Among 620 831 unique adults investigated with echocardiography, there were 17 658 individuals (3.1%) with moderate or greater functional MR (aged 76±13 years, 51%
HCPLive
OCTOBER 27, 2024
New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.
American College of Cardiology
OCTOBER 27, 2024
Two devices approved by the U.S. Food and Drug Administration (FDA) this year for tricuspid regurgitation (TR) are safe, effective and improve quality of life (QOL) at one year, according to studies published in JACC and simultaneously being presented at TCT 2024.
HCPLive
OCTOBER 27, 2024
This interview features a discussion with Bhatia and Ferris regarding the necessity of collaboration between dermatologists and oncologists for skin cancer.
HeartRhythm
OCTOBER 27, 2024
Calmodulinopathy is a rare genetic disorder caused by mutations in the calmodulin genes, often presenting with malignant ventricular arrhythmias during infancy or early childhood.1,2 Despite aggressive management with standard therapies, the prognosis remains poor. We present a case of a neonate with severe QTc prolongation due to a CALM1 gene variant.
HCPLive
OCTOBER 27, 2024
Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.
HeartRhythm
OCTOBER 27, 2024
Esophageal cancer is the sixth leading cause of cancer-related mortality worldwide; with esophageal adenocarcinoma being the more common subtype in the West. For patients with localized or locally advanced esophageal adenocarcinoma, esophagectomy is necessary for pursuing a curative intent approach. One of the standard approaches typically involves neoadjuvant concurrent chemoradiation with carboplatin and paclitaxel followed by esophagectomy, as established by the phase III CROSS trial [1].
HCPLive
OCTOBER 27, 2024
The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.
HeartRhythm
OCTOBER 27, 2024
Sudden cardiac death (SCD) remains a major health problem in all continents. It usually affects older patients suffering from coronary artery disease and cardiomyopathies. However, a morphologically normal heart during autopsy has been a frequent finding, ranging from 40% to 78% in victims aged 10 to 49 years old (1-5). This group of patients defines the sudden arrhythmic death syndrome (SADS) where the cause of death is unknown.
HCPLive
OCTOBER 27, 2024
Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.
American College of Cardiology
OCTOBER 27, 2024
New science presented at TCT 2024 and simultaneously published across the family of JACC Journals sheds light on topics including photon-counting detector-computed tomography (PCD-CT), new and emerging technologies for treating patients with cardiovascular diseases, fractional flow reserve (FFR) and resting full-cycle ratio for predicting myocardial ischemia, intravascular ultrasound (IVUS)-guided PCI in patients with diabetes and acute coronary syndrome (ACS), left atrial appendage occlusion (L
HCPLive
OCTOBER 27, 2024
New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.
HeartRhythm
OCTOBER 27, 2024
Little has been reported on the predictors of late recurrence (LR) after second radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF).
HCPLive
OCTOBER 27, 2024
This Fall Clinical Dermatology Conference interview with Song features a discussion regarding several useful clinical pearls for dermatologists.
American College of Cardiology
OCTOBER 27, 2024
What is the clinical impact of tricuspid regurgitation (TR) reduction with tricuspid transcatheter edge-to-edge repair (T-TEER)?
HCPLive
OCTOBER 27, 2024
The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.
CardiacWire
OCTOBER 27, 2024
It’s well known that heart disease is the U.S.’s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. Heart Disease in 2050 – The AHA warned of massive heart disease increases by 2050, spanning CVD (+60%), diabetes (+100%), obesity (+70%), hypertension (+44%), heart failure (+66%), and stroke (+100%).
HCPLive
OCTOBER 27, 2024
Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.
Expert insights. Personalized for you.
85 
Let's personalize your content